Compound ID | 1829

Update compound information

CMTX-001

Class: Antibody

Agent Type: Direct acting; Antibiofilm;
Mechanism of action: Targets DNABII proteins (bacterial DNA-binding proteins) which stabilize and maintain the integrity of bacterial biofilms; DNABII inhibitor
Combined with other compounds: Yes
Description: Humanized monoclonal antibody
Institute where first reported: Clarametyx
Year first mentioned: 2020
Highest development stage: Phase 1/Phase 2 (NCT06159725)
Development status: Active
External links:
Citations:
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773079/
  • https://www.businesswire.com/news/home/20200504005153/en/Clarametyx-Biosciences-Launches-With-an-Ambitious-Strategy-to-Address-Life-threatening-Bacterial-Infections

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.